FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000335189> ?p ?o ?g. }

• W3000335189 endingPage "iv16" @default.
• W3000335189 startingPage "iv16" @default.
• W3000335189 abstract "ABSTRACT Introduction Aflibercept is a recombinant human fusion protein that acts as a decoy receptor preventing VEGF-A, VEGF-B, and PlGF from interacting with their receptors. The phase 3 VELOUR study demonstrated a statistically significant survival benefit with the combination of aflibercept + FOLFIRI in metastatic colorectal cancer (mCRC) patients who had progressed during or after prior oxaliplatin-based chemotherapy. Modified (m) FOLFOX6 is an established first-line regimen for patients with mCRC. Preclinical and clinical evidence supported the evaluation of aflibercept + mFOLFOX6 for the first-line treatment of patients with mCRC. An mFOLFOX6 study arm was included as a calibrator; the study was not powered for a statistical comparison. Methods The primary endpoint was progression-free survival rate at 12 months (PFS12). A secondary objective was to explore biomarkers. Patients with previously untreated mCRC, ECOG PS 0-2, and adequate organ function were randomized 1:1 to receive aflibercept 4 mg/kg + mFOLFOX6 (A) or mFOLFOX6 (B), every 2 weeks, and were stratified by ECOG PS (0-1/2), prior adjuvant therapy (yes/no), and metastases confined to liver (yes/no). Patients were to be treated to disease progression. PFS12 rate and objective response rate were assessed according to RECIST criteria by an Independent Review Committee blinded to treatment allocation. Results From March 2009 to April 2010, 236 patients (median age, 62.5 years; male, 61% PS 0-1, 97.5% prior adjuvant therapy, 10.2% liver metastases only, 28.4%) were randomized to A (n = 119) or B (n = 117). Baseline characteristics were similar in both arms. PFS12 was 25.8% (95% CI: 17.2-34.4) for A and 21.2% (95% CI: 12.2-30.3) for B. Response rate was 49.1% (95% CI: 39.7-58.6) in arm A and 45.9% (95% CI: 36.4-55.7) in arm B, and median PFS was 8.48 months (95% CI: 7.89-9.92) in arm A and 8.77 months (95% CI: 7.62-9.27) in arm B. Overall survival data had limited maturity, with less than 43% death events in each arm. Grade 3-4 adverse events with >5% higher incidence in arm A relative to arm B were hypertension, proteinuria, neutropenia, diarrhea, and infections. Biomarker data will be presented at the meeting. Conclusion In this phase 2 study, PFS12 with aflibercept + mFOLFOX6 appeared to be similar to mFOLFOX6, although the study was not powered for comparison. The biomarker analyses and clinical interpretation will be presented at the meeting. The safety profile of aflibercept was consistent with that seen in prior studies." @default.
• W3000335189 created "2020-01-23" @default.
• W3000335189 creator A5005636341 @default.
• W3000335189 creator A5008173055 @default.
• W3000335189 creator A5012667192 @default.
• W3000335189 creator A5013949384 @default.
• W3000335189 creator A5016992044 @default.
• W3000335189 creator A5017763783 @default.
• W3000335189 creator A5040081800 @default.
• W3000335189 creator A5040135194 @default.
• W3000335189 creator A5047925415 @default.
• W3000335189 creator A5053714452 @default.
• W3000335189 creator A5064851637 @default.
• W3000335189 date "2012-06-01" @default.
• W3000335189 modified "2023-10-01" @default.
• W3000335189 title "O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM)" @default.
• W3000335189 doi "https://doi.org/10.1016/s0923-7534(19)66488-4" @default.
• W3000335189 hasPublicationYear "2012" @default.
• W3000335189 type Work @default.
• W3000335189 sameAs 3000335189 @default.
• W3000335189 citedByCount "23" @default.
• W3000335189 countsByYear W30003351892012 @default.
• W3000335189 countsByYear W30003351892013 @default.
• W3000335189 countsByYear W30003351892014 @default.
• W3000335189 countsByYear W30003351892015 @default.
• W3000335189 countsByYear W30003351892016 @default.
• W3000335189 countsByYear W30003351892017 @default.
• W3000335189 countsByYear W30003351892020 @default.
• W3000335189 crossrefType "journal-article" @default.
• W3000335189 hasAuthorship W3000335189A5005636341 @default.
• W3000335189 hasAuthorship W3000335189A5008173055 @default.
• W3000335189 hasAuthorship W3000335189A5012667192 @default.
• W3000335189 hasAuthorship W3000335189A5013949384 @default.
• W3000335189 hasAuthorship W3000335189A5016992044 @default.
• W3000335189 hasAuthorship W3000335189A5017763783 @default.
• W3000335189 hasAuthorship W3000335189A5040081800 @default.
• W3000335189 hasAuthorship W3000335189A5040135194 @default.
• W3000335189 hasAuthorship W3000335189A5047925415 @default.
• W3000335189 hasAuthorship W3000335189A5053714452 @default.
• W3000335189 hasAuthorship W3000335189A5064851637 @default.
• W3000335189 hasBestOaLocation W30003351891 @default.
• W3000335189 hasConcept C121608353 @default.
• W3000335189 hasConcept C126322002 @default.
• W3000335189 hasConcept C143998085 @default.
• W3000335189 hasConcept C168563851 @default.
• W3000335189 hasConcept C2776694085 @default.
• W3000335189 hasConcept C2777802072 @default.
• W3000335189 hasConcept C2778749236 @default.
• W3000335189 hasConcept C3019800554 @default.
• W3000335189 hasConcept C31760486 @default.
• W3000335189 hasConcept C526805850 @default.
• W3000335189 hasConcept C535046627 @default.
• W3000335189 hasConcept C71924100 @default.
• W3000335189 hasConceptScore W3000335189C121608353 @default.
• W3000335189 hasConceptScore W3000335189C126322002 @default.
• W3000335189 hasConceptScore W3000335189C143998085 @default.
• W3000335189 hasConceptScore W3000335189C168563851 @default.
• W3000335189 hasConceptScore W3000335189C2776694085 @default.
• W3000335189 hasConceptScore W3000335189C2777802072 @default.
• W3000335189 hasConceptScore W3000335189C2778749236 @default.
• W3000335189 hasConceptScore W3000335189C3019800554 @default.
• W3000335189 hasConceptScore W3000335189C31760486 @default.
• W3000335189 hasConceptScore W3000335189C526805850 @default.
• W3000335189 hasConceptScore W3000335189C535046627 @default.
• W3000335189 hasConceptScore W3000335189C71924100 @default.
• W3000335189 hasLocation W30003351891 @default.
• W3000335189 hasOpenAccess W3000335189 @default.
• W3000335189 hasPrimaryLocation W30003351891 @default.
• W3000335189 hasRelatedWork W1964567729 @default.
• W3000335189 hasRelatedWork W1967397018 @default.
• W3000335189 hasRelatedWork W1975145172 @default.
• W3000335189 hasRelatedWork W2343662197 @default.
• W3000335189 hasRelatedWork W2392730113 @default.
• W3000335189 hasRelatedWork W2809641293 @default.
• W3000335189 hasRelatedWork W3004259476 @default.
• W3000335189 hasRelatedWork W3013399233 @default.
• W3000335189 hasRelatedWork W3159250744 @default.
• W3000335189 hasRelatedWork W4256514411 @default.
• W3000335189 hasVolume "23" @default.
• W3000335189 isParatext "false" @default.
• W3000335189 isRetracted "false" @default.
• W3000335189 magId "3000335189" @default.
• W3000335189 workType "article" @default.